Ascendis Wins FDA Approval For Rare Disease Therapy

Ascendis Pharma A/S (NASDAQ:ASND) shares are up during Monday’s premarket session following the FDA’s approval of Yuviwel (navepegritide; developed as TransCon CNP), the first and only once-weekly treatment for children with achondroplasia. FDA Approval The FDA...